EUROPEAN JOURNAL OF HAEMATOLOGY欧洲血液学杂志
EUROPEAN JOURNAL OF HAEMATOLOGY(英文缩写 EUR J HAEMATOL),ISSN 0902-4441,eISSN 1600-0609,中文译名:欧洲血液学杂志 是一本学术期刊。本页汇总该期刊的最新影响因子、分区信息以及最新收录于 PubMed 的文献,帮助您快速了解期刊全貌。
发文量统计区间：2025-09-27 至 2026-09-27，按本站收录文献的发表日期统计。
期刊介绍
历年影响因子趋势
| JCR 数据年份 | 影响因子 | JCR 分区 |
|---|---|---|
| 2021 | 3.674 | Q3 |
| 2022 | 3.100 | Q3 |
| 2023 | 2.300 | Q2 |
| 2024 | 2.300 | Q2 |
| 2025 | 2.600 | Q2 |
EUROPEAN JOURNAL OF HAEMATOLOGY 最新收录文献
-
1. Vitamin B12 Deficiency in Sickle Cell Disease: Method-Driven Estimates and Systematic Diagnostic Misclassification.
PMID:日期:2026-10-01To determine whether the reported 0%-70% prevalence of vitamin B12 deficiency in sickle cell disease (SCD) reflects true population variation or diagnostic misclassification. We conducted a PRISMA 2020-compliant systematic review of observational studies (January 1, 2000-May 13, 2026; PROSPERO CRD420251087800) assessing B12 status in SCD. PubMed, AJOL, and Google Scholar were searched with citation tracking and dual screening. Diagnostic validity was assessed across biomarker strategy, analytical platform, thresholds, and confounder control using a proposed context-integrated framework to classify methodological robustness and discordance. Fourteen studies were included (57% high-income; 43% LMIC). The evidence base was dominated by limited diagnostic approaches: 71% used immunoassays, over one-third relied on circulating B12 alone, and functional biomarkers were inconsistently applied without systematic confounder adjustment. Prevalence estimates were strongly influenced by diagnostic methods rather than underlying population biology, ranging from 0% to 70% in single-marker studies (mostly 0%-7.1%, with outliers ~50%-70%) and 6.9%-53% in multi-marker studies. Discordance was substantial and greater in LMIC settings than HIC. Current diagnostic approaches in SCD appear method-dependent, generating heterogeneous prevalence estimates with uncertain clinical validity. These findings challenge existing estimates and have implications for clinical practice, research design, and diagnostic equity. ClinicalTrials.gov identifier: CRD420251087800.
-
2. When MRD Is Not MRD: A Context-Dependent Interpretation in Clinical Decision-Making.
PMID:日期:2026-10-01该文献暂无摘要。
-
3. Adapting UK Clinical Practise in Chronic Myeloid Leukaemia in Chronic Phase to Contemporary Management Recommendations: The ADAPT 2.0 Survey.
PMID:日期:2026-10-01Chronic myeloid leukaemia in chronic phase (CML-CP) treatment recommendations have changed substantially in recent years. The ADAPT 2.0 survey aimed to provide an updated understanding of CML-CP management in the UK. This healthcare professional (HCP) survey, conducted between December 2023 and June 2024, assessed treatment goals, choice of tyrosine kinase inhibitors (TKIs), unmet needs and approaches to treatment-free remission (TFR). UK CML-CP practise is generally aligned with the contemporary guidelines for CML management. Key treatment goals were major molecular response (54%-77% across treatment lines) and deep molecular response (5%-46%). The main factors influencing first-line (1 L) TKI selection were treatment guidelines (97%), comorbidities (90%) and TFR as a treatment goal (82%). Therapy switch after one warning European LeukemiaNet (ELN) 2020 response was rare (10% vs. 56% in patients with > 1 warning response and 100% in failure response). BCR::ABL1 mutation analysis was less common after one warning response versus > 1 warning response (54% vs. 82%). TKI toxicity, resistance, intolerance and T315I mutation management were key unmet needs in later treatment lines; achieving and maintaining TFR were key unmet needs in 1 L. The ADAPT 2.0 survey highlights potential areas of improvement in current CML-CP management in the UK.
-
4. Extranodal Marginal Zone Lymphoma: Integrating Etiology, Microenvironment, and Genetics Into Clinical Decision-Making.
PMID:日期:2026-10-01Extranodal marginal zone lymphoma (EMZL) represents a unique paradigm among indolent B-cell neoplasms, in which lymphomagenesis is frequently driven by chronic antigenic stimulation within tissue-specific microenvironments. Persistent infectious or autoimmune triggers promote the development of ectopic lymphoid tissue and sustain B-cell activation, while recurrent genetic alterations-most prominently those that converge on NF-κB signaling-enable progressive escape from antigen dependence. This dual biological foundation explains both the indolent clinical course of most cases and the remarkable therapeutic vulnerability of early-stage, infection-driven disease. Clinically, EMZL arise across a wide range of anatomical sites, each characterized by distinct etiologic associations and patterns of progression. As a result, management strategies must be tailored to disease site, stage, and biological context, with a consistent preference for the least intensive intervention capable of achieving durable disease control. Pathogen-directed antibiotic therapy and involved-site radiotherapy can be curative in localized disease. In contrast, systemic anti-CD20-based immunochemotherapy and targeted agents are reserved for disseminated, refractory, or biologically autonomous lymphomas. Recent advances in molecular profiling, functional imaging, and response assessment are refining risk stratification and treatment selection, shifting therapeutic goals toward early depth of response and quality of life rather than maximal cytotoxic intensity. EMZL thus serves as a model for biologically informed, precision-oriented management of indolent lymphoid malignancies.
-
5. Beyond Frailty Scores: Unmet Needs and Tailored Treatment Strategies in Patients With Chronic Lymphocytic Leukemia Aged ≥ 80 Years.
PMID:日期:2026-10-01Chronic lymphocytic leukemia (CLL) in patients aged ≥ 80 years represents a growing and clinically distinct population that remains underrepresented in clinical trials. Consequently, treatment decisions are often extrapolated from younger or "fit" cohorts, limiting their applicability in routine practice. While targeted therapies (i.e., novel agents such as Bruton tyrosine kinase inhibitors [BTKi] and BCL2 inhibitors) have substantially improved outcomes compared with chemoimmunotherapy, their use in very elderly patients is associated with higher rates of treatment discontinuation, dose reductions, and adverse events. Conventional frailty tools, largely based on comorbidity burden and renal function, fail to capture key age-related vulnerabilities, such as functional decline, cognitive impairment, and reduced physiological reserve. Emerging data suggest that chronological age ≥ 80 years may identify a subgroup with specific clinical behavior and toxicity profiles that are insufficiently characterized by existing assessment models. In summary, elderly patients (aged ≥ 80 years) with CLL should be considered a distinct population requiring individualized, safety-oriented therapeutic approaches. Dedicated clinical trials and adapted treatment algorithms are needed to optimize outcomes in this setting.
-
6. Efficacy and Safety of the C3 Inhibitor Pegcetacoplan in Paroxysmal Nocturnal Hemoglobinuria: A Systematic Review and Meta-Analysis.
PMID:日期:2026-10-01To evaluate the efficacy and safety of the complement C3 inhibitor pegcetacoplan in patients with paroxysmal nocturnal hemoglobinuria (PNH). PubMed, Embase, Web of Science, and Cochrane Library were systematically searched for studies reporting pegcetacoplan use in PNH. Outcomes included transfusion-requirement, hemoglobin normalization, mean hemoglobin levels, lactate dehydrogenase normalization, reticulocyte count normalization, and safety endpoints. Pooled proportions with 95% confidence intervals were calculated using random-effects models, and heterogeneity was assessed using the I statistic. Five studies comprising 271 patients were included. Transfusion avoidance was observed in 80.6% of patients, with a pooled transfusion-requirement rate of 19.4%. LDH normalization occurred in 68.5% of patients (I = 0%). Hemoglobin normalization was observed in 42.9%, while reticulocyte count normalization reached 66%. Any-grade adverse events occurred in 83.5% of patients, most commonly pyrexia, headache, and dizziness. Serious adverse events occurred in 16.6%, decreasing to 12% after sensitivity analysis. Breakthrough hemolysis was reported in 14.8%, and infections in 17%. Pegcetacoplan demonstrates consistent efficacy signals across key hematologic endpoints and an acceptable safety profile, supporting its potential role as an important therapeutic option, particularly in patients with persistent extravascular hemolysis despite C5 inhibition.
-
7. Project Sickle Cure: A Prospective, International Observational Study of Hematopoietic Cell Transplantation for Sickle Cell Disease.
PMID:日期:2026-10-01Sickle cell disease (SCD) is a chronic and life-limiting hemoglobin and systemic vascular disease. While over 1000 people have undergone hematopoietic cell transplantation (HCT) over the last 40 years, long-term disease-specific and health-related quality of life data are lacking. The American Society of Hematology 2021 Guidelines for SCD emphasized the need for more detailed registry data to inform patients and providers with decision-making and practice recommendations. In January 2021, the Sickle Cell Transplant Advocacy and Research Alliance (STAR) launched Project Sickle Cure (PSC). This multi-center, prospective study of patients who have undergone HCT for SCD includes baseline demographics and SCD-specific post-HCT outcomes, serial neurocognitive testing, health-related quality of life measures, health equity evaluations, a neuroimaging bank, detailed evaluation of neurologic status pre- and post-transplant, and chronic pain evaluation. A biorepository is in the planning stage of development. As of November 2025, 115 participants have enrolled at 18 STAR sites with enrollment ongoing. PSC is a STAR prospective study which will address a major gap in our understanding of outcomes post-HCT specific to SCD. WeDecide, a larger study comparing HCT health-related quality of life outcomes to those who receive non-transplant disease modifying therapy (NT-DMT) is in development, and PSC will provide the HCT comparator data. These data will also be highly relevant as other curative and transformative therapies, such as gene therapy, become more widely used.
-
8. Risk Factors of Blood Culture Positivity and Mortality in Bloodstream Infections: A Population-Based Study of Patients With B-Cell Malignancies.
PMID:日期:2026-10-01Bloodstream infections remain a major cause of mortality among cancer patients. Pathogen surveillance and risk stratification tools are key to improved management. This study describes trends in causative pathogens and explores risk factors for positive blood cultures (PBCs) and post-infection mortality in cancer patients. We performed a cohort study of patients diagnosed with a B-cell malignancy in the North Denmark Region between 2013 and 2022, linking cancer registry data to health records. Causative pathogens were described. LASSO regression was used to select variables associated with PBCs and post-infection mortality. Odds ratios were estimated by univariate analyses. Among 1592 patients with B-cell malignancies, 341 patients (21.4%) had at least one PBC, yielding 484 PBCs. We observed a shift from Gram-positive to Gram-negative dominance, driven by an increased frequency of the most common pathogen Escherichia coli (24.8%). Patients with neutropenia, elevated CRP, sepsis, hypotension, or kidney failure had a higher risk of a PBC. Advanced age, kidney failure, and sepsis were all associated with 30- and 90-day post-infection mortality. Routinely available parameters obtained at time of admission were associated with blood culture positivity and mortality. Our findings support the rationale for developing predictive models to individualise infection management.
-
9. Influenza as a Less Commonly Recognized Cause of Hemophagocytic Lymphohistiocytosis: A Systematic Review of Case Reports and Case Series.
PMID:日期:2026-10-01Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening hyper-inflammatory condition that can be triggered by viral infections. However, influenza is not commonly recognized as a cause of HLH, and there is no comprehensive synthesis of influenza-associated HLH in the literature to guide clinicians. We conducted a systematic search of Pubmed and Embase to identify case reports and case series on influenza-associated HLH, and included 29 articles involving 47 patients. Their age ranged from 2 months to 72 years. 67% were males. Influenza A accounted for 91.3% of the cases, predominantly H1N1 (90.2%). All patients had fever, 60% had anemia, 69.7% had thrombocytopenia, 46.6% had leukopenia, 61.3% had splenomegaly, 71.4% had hypertriglyceridemia, and 94.7% had elevated ferritin levels. 97.6% had hemophagocytosis on biopsy. Antiviral therapy was administered in 89.5% of patients. HLH-directed therapy included corticosteroids (77%), intravenous immunoglobulin (36%), and etoposide (23.1%). Intensive care was required in 95.2% of cases. Overall survival was 53.2%. Survival rate was 50% among patients who received either antiviral therapy alone or HLH-directed therapy alone, compared with 65.4% among those who received both. Further studies are necessary to establish standardized diagnostic and therapeutic protocols for influenza-associated HLH.
-
10. Direct Oral Anticoagulants as Primary or Secondary Treatment for Heparin-Induced Thrombocytopenia (HIT) and Associated Thromboembolism (HITT)-A Meta-Analysis.
10. 直接口服抗凝剂作为肝素诱导的血小板减少症（HIT）和相关血栓栓塞症（HITT）的主要或次要治疗——荟萃分析PMID:日期:2026-10-01Heparin-induced thrombocytopenia (HIT) is associated with a high risk for thrombosis. The role of direct oral anticoagulants (DOACs) is still emerging and data are limited considering efficacy and safety among patients with HIT. The aim of this review is to evaluate current data on DOACs as primary or secondary treatment among patients with HIT. This is a systematic review utilising Pubmed, Scopus and Embase online databases. Eligible studies were published up to December 2024 evaluating DOACs as primary or secondary treatment among patients with HIT and/or associated thrombosis (HITT). Primary outcomes included thrombosis rate (TR) and bleeding rate (BR) during follow-up. A total of 44 publications were included (29 case reports, 5 case studies and 10 cohort studies [n > 10 patients]). Regarding treatment, 19 articles evaluated only rivaroxaban, 7 articles only apixaban, 11 articles only dabigatran and 7 articles more than one regimen. A total of 352 patients were included. Overall, 190 patients (53.8%) were given DOAC as primary treatment whereas 162 patients were given a parenteral treatment first and continued with a DOAC. Mean nadir platelet count at diagnosis was 63 000/μL. HITT rate was 190/352 (53.9%; 8% had arterial thrombosis). Mean follow-up was 7.6 months. TR was 20/352 (Pooled proportion = 0.064 [95% CI = 0.042-0.092]) (30% of them were new thromboses without initial thrombosis), and BR was 9/352 (Pooled proportion = 0.039 [95% CI = 0.022-0.062]). Finally, there was no difference found regarding TR and BR between primary or secondary treatment, and among different regimens. DOACs are associated with low rates of thrombosis and major bleeding among patients treated for HIT or HITT, either as primary or secondary treatment. However, the certainty of evidence is very low because of the quality and limitations of the available studies.